CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
儿童肿瘤中在研 CAR-T 细胞免疫治疗简介
英文原题：Briefing on Investigational Chimeric Antigen Receptor T-Cell Immunotherapies in Pediatric Neoplasms.
查看英文原题
Briefing on Investigational Chimeric Antigen Receptor T-Cell Immunotherapies in Pediatric Neoplasms.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
tisagenlecleucel（Kymriah）作为首创嵌合抗原受体（CAR）T 细胞免疫疗法，在难治性血液系统恶性肿瘤治疗中取得良好结果，推动新型 CAR-T 构建体、靶点和不同代次 CAR-T 的研究与临床测试迅速发展。药师可能会接到关于正在进行的临床试验的咨询，也可能参与试验患者的治疗照护。本简报介绍正在开展的临床试验，这些试验探索 CAR-T 新型免疫疗法用于儿童难治性血液系统和实体器官来源恶性肿瘤。本文可帮助临床实践者了解快速发展的 CAR-T 免疫疗法领域。
展开英文摘要原文
The promising results seen in the treatment of refractory hematologic malignancies with tisagenlecleucel (Kymriah), the pioneering Chimeric Antigen Receptor (CAR) T-cell immunotherapy, has stimulated a fast growth in research and clinical testing of novel CAR-T constructs, targets, and various generations of CAR T-cells.
Pharmacists may receive inquiries about active clinical trials or may be contributing to the care of patients participating in these studies. This briefing discusses the on-going clinical trials that explore novel CAR T-cell immunotherapies in pediatric refractory malignancies of hematologic and solid organ origins. It can be valuable in assisting practitioners in navigating the rapidly evolving field of CAR T-cell immunotherapies.
论文信息
- 作者
- Stawicki B、Schacher T、Dushenkov A、Jungsuwadee P
- 单位
- Fairleigh Dickinson University School of Pharmacy, Florham Park, NJ, USA.United States
- 文献类型
- 综述
- 期刊
- Journal of pharmacy practice2024 Dec
- 原文标识
- PubMed 38718427 · DOI 10.1177/08971900241247619